Lesson of Beyon SCENIC consensus
Patients with Crohn’s disease affecting the colon and ulcerative colitis are known to be at increased risk for
the development of dysplasia and colorectal cancer
(CRC).1,2 Unlike patients with sporadic CRC, patients
with longstanding inflammatory bowel disease (IBD)
who develop malignancy do so through different
pathophysiologic mechanisms and with foreshortened time frames.3,4 Furthermore, the gross appearance of
dysplasia exhibits greater morphologic range in IBD
patients, with subtler, flat lesions being commonplace.5
Reassuringly, in the era of biologic therapies, rates of
IBD-related CRC and CRC-associated mortality have
declined.6 This shift in prevalence has coincided with
improved colonoscopic resolution and the adoption of...